Instinct Science's New AI Bets Proprietary Content Beats ChatGPT

About four in ten veterinary professionals already use AI tools regularly, and the American Veterinary Medical Association's own delegates have said they are uncomfortable with AI acting as an independent clinical decision maker. Instinct Science, the company that owns Plumb's Veterinary Drugs and Clinician's Brief, just launched a product built for exactly that discomfort: an AI assistant called Attending that answers clinical questions using only its own peer-reviewed content. The bet is that a decade of proprietary clinical publishing is worth more as an AI moat than as a subscription business alone.

Instinct Science launches Attending for veterinarians

Instinct Science announced Attending on September 10th, 2026. The tool answers a veterinarian's plain-language clinical question with a specialty-level response in seconds, then attaches inline citations the vet can verify in one tap.

The answers come exclusively from the company's own library: Plumb's Veterinary Drugs, Standards of Care, and Clinician's Brief, maintained by a team of more than 200 boarded specialists and pharmacists. Drug dosing and other safety-critical figures are retrieved directly from Plumb's rather than generated by the model, a distinction the company is using to draw a hard line against general-purpose chatbots.

Attending is currently in an invitation-only research preview with veterinarians at "leading centers" across the US, including Schwarzman Animal Medical Center in New York, where Dennis Slade, head of internal medicine, said the tool has proven useful for complex cases, questions, and teaching. A standalone product and versions embedded directly in Instinct's EMR and ScribbleVet software are both promised "in the coming months." The company plans to show Attending publicly for the first time at the IVECCS emergency and critical care conference in Savannah, Georgia, September 14th through 17th.

Proprietary content becomes vet software's new moat

The habit Attending is built to intercept is already widespread rather than hypothetical. Emergency clinics run overnight with one doctor on the floor and no specialist to page, and general AI chatbots are fast, free, and already open in a browser tab. AVMA's reference committee flagged the same tension in July: professionals lean on AI for administrative and organizational work but resist it as a stand-alone clinical decision maker, and want human oversight scaled to how high-stakes the task is. Drug dosing, the exact question Attending is built to answer, sits about as high-stakes as veterinary decisions get. That gap between comfort level and existing habit is what Instinct Science has spent four years positioning itself to close.

Instinct took a minority growth investment from Mainsail Partners in 2022, then used the capital to acquire VetMedux in January 2024, folding Clinician's Brief and Plumb's Veterinary Drugs into the same company as its existing EMR and dictation software. Attending is the payoff of that consolidation: content that used to be sold as a standalone subscription now doubles as the retrieval base for a product that general competitors cannot easily copy, because they do not own the underlying references.

That is a different bet than most of the veterinary AI launches this year. VetRec's ambient scribing tool automates the documentation a vet already knows how to write, a lower-stakes problem. Wolters Kluwer is trying to license its way into the same drug-reference category Plumb's already owns outright. Attending is a bet on the harder, higher-liability problem: automating the judgment call itself, in a specialty where a wrong dosing answer is a malpractice exposure, not just a bad customer experience.

The operator question is whether "grounded in peer-reviewed content, with citations" is a big enough difference to change a habit that already feels good enough for free. Instinct's answer is a narrow one: keep the model out of dosing entirely, and make every claim checkable in one tap. Whether that combination changes behavior in a busy ER, versus a careful prompt to a general chatbot, is the thing no press release can settle.

IVECCS debut this month will test demand

Attending's invitation-only phase means the real test hasn't started. IVECCS gives Instinct its first public airing in front of emergency and critical-care specialists, precisely the audience the 2am-question pitch targets.

Two decisions after the conference will say more than the demo does. The first is pricing: whether Attending ships as a new line item or gets folded into existing Plumb's and Clinician's Brief subscriptions. A standalone SKU would signal that Instinct believes AI retrieval is worth paying for on its own, separate from the underlying content. The second is timing: whether the standalone product and the EMR-embedded version inside Instinct EMR and ScribbleVet land together or drift apart, since embedding decision support directly inside a workflow a vet already uses daily is what turns a reference tool into a habit rather than a tab they forget to open.

Whichever company answers those two questions fastest sets the template that other veterinary software vendors, and the vets already leaning on general AI tools without one, will have to respond to.

Source: Instinct Science via GlobeNewswire